Sulieman Abusrewil

Learn More
Serum thyroid stimulating hormone and thyroxine concentrations were monitored in 42 infants who had been treated for congenital hypothyroidism. Serum thyroid stimulating hormone concentrations were raised in 22 of the infants (52%) at 2 to 4 months, in 16 (38%) at 5 to 11 months, in 14 (33%) at 12 to 18 months, and in eight (19%) at 2 to 4 years. Serum(More)
We describe three children, now aged between 5 and 6 years, with a persistent mild hyperthyrotropinaemia since the neonatal period and normal levels of thyroid hormones. The increased thyroid stimulating hormone concentration is not artefactual and is not caused by antibody interferences. Their growth and development is normal and none has received thyroid(More)
UNLABELLED Diabetes mellitus is a common autoimmune endocrine disorder associated with organ-specific autoantibodies which are frequently detected at the time of diagnosis. Some of these antibodies are specific to the pancreas (GAD, IA2, ICA) while others are related to different autoimmune diseases. AIM OF THE STUDY To define the prevalence of thyroid(More)
OBJECTIVE To determine the genetic profile of celiac disease (CD) in Libyan children with type 1 diabetes as there are no data on the frequency of human leukocyte antigen (HLA)-related CD-predisposing genes in diabetic patients in Libya. METHODS We randomly studied 218 Libyan type 1 diabetic children. The mean age was 12.2±4.6 years; 56% were female(More)
Thyroid function was assessed in three selected groups of children who had survived cancer. Children in group 1 had received radiotherapy to the thyroid area, group 2 had radiotherapy to the thyroid area and adjuvant chemotherapy, and group 3 had chemotherapy with or without radiotherapy away from the thyroid area. There were 75 survivors and 63 (40 boys,(More)
Aminoglutethimide (AG) inhibits steroid bio-synthesis and the peripheral conversion of androgens to oestrogens (Santen et al., 1978; Dexter et al., 1967). Aminoglutethimide has proved to be an effective therapy in advanced breast cancer with response rates of 37.5-50% (Wells et al., 1978; Harris et al., 1983) and duration of response similar to(More)
  • 1